Treatment of Ulcerative Colitis with a Humanized Antibody to the α4β7Integrin
- 16 June 2005
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 352 (24), 2499-2507
- https://doi.org/10.1056/nejmoa042982
Abstract
Selective blockade of interactions between leukocytes and vascular endothelium in the gut is a promising strategy for the treatment of inflammatory bowel diseases.Keywords
This publication has 29 references indexed in Scilit:
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseNew England Journal of Medicine, 2003
- The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro‐drugs used in the management of ulcerative colitisAlimentary Pharmacology & Therapeutics, 2002
- Antibody humanization: a case of the ‘Emperor’s new clothes’?Immunology Today, 2000
- An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis (UC)Gastroenterology, 2000
- Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7Gastroenterology, 1996
- Two Signal Activation as an Explanation of High Zone Tolerance: A Mathematical Exploration of the Nature of the Second SignalJournal of Theoretical Biology, 1994
- Microscopic activity in ulcerative colitis: what does it mean?Gut, 1991
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987
- Replacing the complementarity-determining regions in a human antibody with those from a mouseNature, 1986
- Variation Between Observers in Describing Mucosal Appearances in ProctocolitisBMJ, 1964